BeOne Medicines AG (ONC)

Market Cap	33.69B +20.3%
Revenue (ttm)	5.34B +40.2%
Net Income	286.93M
EPS	2.47
Shares Out	110.89M
PE Ratio	123.00
Forward PE	55.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	194,629
Open	301.22
Previous Close	302.49
Day's Range	299.29 - 304.91
52-Week Range	196.45 - 385.22
Beta	0.54
Analysts	Strong Buy
Price Target	374.75 (+23.35%)
Earnings Date	May 6, 2026

About ONC

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 12,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://beonemedicines.com

Analyst Summary

According to 12 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $374.75, which is an increase of 23.35% from the latest price.

Price Target

$374.75

(23.35% upside)

Analyst Consensus: Strong Buy